This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Analyst's Celldex Call Another Sign Of Biotech Stock Bubble

NEW YORK (TheStreet) -- Biotech stock bubble alert: On Wednesday, Oppenheimer analyst Boris Peaker jacks his Celldex Therapeutics (CLDX - Get Report) price target to $40 from $25. Why? Because Peaker predicts an experimental Celldex cancer drug with no human clinical data today will deliver $8 billion (!!!) in sales in 2025. 

Peaker:

Our valuation revision is based on the addition of CDX-1127 to our model. We did not make any changes to our valuation of rindo ($5/share), CDX-011 ($18/share), CDX-1135 ($2/share), and added CDX-1127 ($15/share). We believe that CDX-1127 holds the largest commercial potential compared to CDLX's other assets. However, given the early stage of development, we assume only a 15% probability of success for CDX-1127 at this time and look toward the anticipated data in November to further refine our CDX-1127 NPV. 

A 15% probability of success for CDX-1127 yet it's still worth $15 per share to Celldex today. Why peak out at only $8 billion in sales? Why not $10 billion? $20 billion? You're just throwing darts blindfolded, Boris, so why not go really big? 

We've seen sell-side analysts gin up a lot of crazy excuses to justify higher valuations for development-stage biotech companies these days, but Peaker's rationalization for Celldex is preposterous. 

David Sobek believes the only bubble in biotech today is people warning/complaining about biotech stock bubbles. But the housing bubble began when real estate brokers start selling split-level ranches in Kissimmee, Fla, for $2 million each without anyone raising an eyebrow. Peering 12 years into the future to predict $8 billion in sales for a drug with no clinical data today is no different. 

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CLDX $29.39 -1.31%
AAPL $126.60 0.15%
FB $80.00 -1.48%
GOOG $567.68 -1.33%
TSLA $193.88 -3.36%

Markets

DOW 17,856.78 -278.94 -1.54%
S&P 500 2,071.26 -29.78 -1.42%
NASDAQ 4,927.37 -55.4390 -1.11%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs